Virax Biolabs Proposes Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

Virax Biolabs will hold an Extraordinary General Meeting on June 5, 2026, to vote on a reverse stock split, ranging from 10-for-1 to 30-for-1, aimed at meeting Nasdaq's minimum bid price requirement and avoiding delisting.

check_boxKey Events

• Shareholder Meeting Scheduled

  An Extraordinary General Meeting of Shareholders is set for June 5, 2026, to vote on key proposals.

• Reverse Stock Split Proposal

  Shareholders will vote on a proposal to effect a reverse stock split at a ratio between 10-for-1 and 30-for-1, with the exact ratio to be determined by the Board.

• Nasdaq Compliance Objective

  The primary purpose of the reverse split is to increase the per-share price to regain compliance with Nasdaq's $1.00 minimum bid price rule by the July 11, 2026 deadline, thereby preventing delisting.

• Board Recommendation

  The Board of Directors unanimously recommends that shareholders vote 'FOR' the reverse stock split and related charter amendment.

auto_awesomeAnalysis

Virax Biolabs is seeking shareholder approval for a reverse stock split, a critical measure to regain compliance with Nasdaq's minimum bid price requirement. Failure to achieve a $1.00 per share closing bid price by July 11, 2026, could lead to delisting, which would severely impact the stock's liquidity and marketability, potentially limiting investor access and future capital raises. The proposed split ratio of 10-for-1 to 30-for-1 indicates the significant challenge the company faces in maintaining its listing.